Format

Send to

Choose Destination
See comment in PubMed Commons below
Neurology. 2003 Nov 11;61(9):1282-4.

A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barré syndrome.

Author information

1
Department of Clinical Neurosciences, Guy's, King's & St. Thomas' School of Medicine, London, UK.

Abstract

The authors recruited 19 nonambulant patients with Guillain-Barré syndrome into a pilot, double-blind, randomized, placebo-controlled safety trial of interferon beta 1a (IFN[beta]-1a) (Rebif). Participants received IFN[beta]-1a or placebo subcutaneously three times weekly, 22 microg for the first week and then 44 microg for up to 24 weeks, in addition to IV immunoglobulin (IVIg). IFN[beta] did not have any unexpected interaction with IVIg and there was no significant difference in rate of improvement.

PMID:
14610140
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center